TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Percheron Therapeutics ( (AU:PER) ).
Percheron Therapeutics Limited has announced the date for its Annual General Meeting (AGM) on October 22, 2025, in Melbourne, Australia. The company has also released its FY 2025 Annual Report and looks forward to shareholder participation at the AGM. This announcement is part of Percheron’s ongoing efforts to engage with stakeholders and provide updates on its operations and strategic direction.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for oncology and rare diseases. Its lead program, HMBD-002, is a monoclonal antibody targeting the immune checkpoint regulator, VISTA, which has completed a phase I clinical trial showing safety and tolerability.
Average Trading Volume: 3,569,710
Technical Sentiment Signal: Sell
Current Market Cap: A$11.42M
For detailed information about PER stock, go to TipRanks’ Stock Analysis page.